Nuveen
TNGX icon

Nuveen’s Tango Therapeutics TNGX Stock Holding History

Nuveen’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.8M Buy
890,170
+529,352
+147% +$13.1M 0.01% 1053
2026
Q1 		$7.55M Buy
360,818
+60,377
+20% +$840K ﹤0.01% 1712
2025
Q4 		$2.66M Sell
300,441
-627,571
-68% -$5.41M ﹤0.01% 2171
2025
Q3 		$7.8M Buy
928,012
+485,049
+110% +$3.28M ﹤0.01% 1693
2025
Q2 		$2.27M Buy
442,963
+240,780
+119% +$595K ﹤0.01% 2248
2025
Q1 		$277K Buy
202,183
+9,924
+5% +$24.4K ﹤0.01% 3056
2024
Q4 		$594K Sell
192,259
-12,562
-6% -$58.3K ﹤0.01% 2925
2024
Q3 		$1.58M Sell
204,821
-449
-0.2% -$4.29K ﹤0.01% 2538
2024
Q2 		$1.76M Sell
205,270
-143,066
-41% -$1.11M ﹤0.01% 2446
2024
Q1 		$2.77M Sell
348,336
-71,210
-17% -$763K ﹤0.01% 2253
2023
Q4 		$4.15M Buy
419,546
+238,077
+131% +$2.07M ﹤0.01% 2080
2023
Q3 		$2.04M Buy
181,469
+10,246
+6% +$62.5K ﹤0.01% 2285
2023
Q2 		$568K Buy
171,223
+9,440
+6% +$34K ﹤0.01% 2883
2023
Q1 		$639K Sell
161,783
-6,780
-4% -$39.3K ﹤0.01% 2749
2022
Q4 		$1.22M Buy
168,563
+5,363
+3% +$37.7K ﹤0.01% 2605
2022
Q3 		$591K Sell
163,200
-134
-0.1% -$572 ﹤0.01% 2923
2022
Q2 		$740K Buy
163,334
+119,055
+269% +$721K ﹤0.01% 2912
2022
Q1 		$338K Buy
+44,279
New +$384K ﹤0.01% 3100

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Nuveen's TNGX Position: Q2 2026 in Review

Nuveen increased its Tango Therapeutics (TNGX) stake by 147% in Q2 2026, buying an estimated $13.1M and bringing the position to 890,170 shares worth $27.8M. The position accounts for 0.01% of the portfolio, ranked #1053.

Nuveen first reported a position in TNGX in Q1 2022 and has held it in 18 quarters since. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Nuveen held 890,170 shares of Tango Therapeutics worth $27.8M as of Q2 2026.
  • Nuveen bought 529,352 Tango Therapeutics shares in Q2 2026, an estimated $13.1M.
  • Tango Therapeutics made up 0.01% of Nuveen's portfolio in Q2 2026, its #1053 holding.
  • Nuveen first reported a position in Tango Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • 249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.